Literature DB >> 28993263

Angiotensin 1-7 in the rostro-ventrolateral medulla increases blood pressure and splanchnic sympathetic nerve activity in anesthetized rats.

Mark S Bilodeau1, J C Leiter2.   

Abstract

Angiotensin 1-7 (ANG-(1-7)), a derivative of angiotensin I or II, is involved in the propagation of sympathetic output to the heart and vasculature, and the receptor for ANG-(1-7), the Mas receptor, is expressed on astrocytes in the rostral ventrolateral medulla (RVLM). We recorded blood pressure (BP) and splanchnic sympathetic nerve activity (SSNA) before and after focal injection of ANG-(1-7) into the RVLM of rats. Unilateral injection of ANG-(1-7) into the RVLM, acting through the Mas receptor, increased SSNA and BP, and glutamate receptor antagonists, CNQX and D-AP5, partially reduced the ANG-(1-7) effect. ATP is often co-released with glutamate, and blocking ATP with PPADS also reduced the pressor response to microinjection of ANG-(1-7) within the RVLM. The effects of ANG-(1-7) were blocked by the MAS receptor antagonist, A-779 (which had no consistent effect on blood pressure or sympathetic nerve activity when injected on its own). We conclude that astrocytes in the RVLM participate in central, angiotensin-dependent regulation of blood pressure and sympathetic nerve activity, and the Mas receptor, when activated by ANG-(1-7), elicits the release of the gliotransmitters, glutamate and ATP. These gliotransmitters then cause an increase in sympathetic nerve activity and blood pressure by interacting with AMPA/kainate and P2X receptors in the RVLM.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ANG-(1-7); Astrocytes; Blood pressure; Central renin angiotensin system; Sympathetic nervous system

Mesh:

Substances:

Year:  2017        PMID: 28993263     DOI: 10.1016/j.resp.2017.10.003

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  6 in total

Review 1.  The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications.

Authors:  Amanda J Miller; Amy C Arnold
Journal:  Clin Auton Res       Date:  2018-11-09       Impact factor: 4.435

Review 2.  Diabetes and COVID-19: evidence, current status and unanswered research questions.

Authors:  Ritesh Gupta; Akhtar Hussain; Anoop Misra
Journal:  Eur J Clin Nutr       Date:  2020-05-13       Impact factor: 4.016

3.  Comment on "Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade".

Authors:  Erkan Cure; Medine Cumhur Cure
Journal:  Nephron       Date:  2020-04-20       Impact factor: 2.847

4.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.

Authors:  Erkan Cure; Medine Cumhur Cure
Journal:  Diabetes Metab Syndr       Date:  2020-04-15

Review 5.  Sympathetic activation: a potential link between comorbidities and COVID-19.

Authors:  Andrea Porzionato; Aron Emmi; Silvia Barbon; Rafael Boscolo-Berto; Carla Stecco; Elena Stocco; Veronica Macchi; Raffaele De Caro
Journal:  FEBS J       Date:  2020-08-01       Impact factor: 5.542

6.  The potential role of the carotid body in COVID-19.

Authors:  Andrea Porzionato; Aron Emmi; Elena Stocco; Silvia Barbon; Rafael Boscolo-Berto; Veronica Macchi; Raffaele De Caro
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-05       Impact factor: 5.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.